1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Biokine Therapeutics Ltd. - Product Pipeline Review - 2013

Biokine Therapeutics Ltd. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 19 pages

Biokine Therapeutics Ltd. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Biokine Therapeutics Ltd. - Product Pipeline Review - 2013” provides data on the Biokine Therapeutics Ltd.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Biokine Therapeutics Ltd.’s corporate website, SEC filings, investor presentations and featured press releases, both from Biokine Therapeutics Ltd. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Biokine Therapeutics Ltd. - Brief Biokine Therapeutics Ltd. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Biokine Therapeutics Ltd. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Biokine Therapeutics Ltd. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Biokine Therapeutics Ltd.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Biokine Therapeutics Ltd.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Biokine Therapeutics Ltd. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Biokine Therapeutics Ltd.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Biokine Therapeutics Ltd..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Biokine Therapeutics Ltd. and identify potential opportunities in those areas.

Table Of Contents

Biokine Therapeutics Ltd. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Biokine Therapeutics Ltd. Snapshot 4
Biokine Therapeutics Ltd. Overview 4
Key Information 4
Key Facts 4
Biokine Therapeutics Ltd. - Research and Development Overview 5
Key Therapeutic Areas 5
Biokine Therapeutics Ltd. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Out-Licensed Products/Combination Treatment Modalities 9
Biokine Therapeutics Ltd. - Pipeline Products Glance 10
Biokine Therapeutics Ltd. - Early Stage Pipeline Products 10
Pre-Clinical Products/Combination Treatment Modalities 10
Biokine Therapeutics Ltd. - Drug Profiles 11
BKT-130 IV 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
BKT-150 IV 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Biokine Therapeutics Ltd. - Pipeline Analysis 13
Biokine Therapeutics Ltd. - Pipeline Products by Therapeutic Class 13
Biokine Therapeutics Ltd. - Pipeline Products by Route of Administration 14
Biokine Therapeutics Ltd. - Pipeline Products By Mechanism of Action 15
Biokine Therapeutics Ltd. - Dormant Projects 16
Biokine Therapeutics Ltd. - Locations And Subsidiaries 17
Head Office 17
Appendix 18
Methodology 18
Coverage 18
Secondary Research 18
Primary Research 18
Expert Panel Validation 18
Contact Us 19
Disclaimer 19

List of Tables


Biokine Therapeutics Ltd., Key Information 4
Biokine Therapeutics Ltd., Key Facts 4
Biokine Therapeutics Ltd. - Pipeline by Indication, 2013 6
Biokine Therapeutics Ltd. - Pipeline by Stage of Development, 2013 7
Biokine Therapeutics Ltd. - Monotherapy Products in Pipeline, 2013 8
Biokine Therapeutics Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2013 9
Biokine Therapeutics Ltd. - Pre-Clinical, 2013 10
Biokine Therapeutics Ltd. - Pipeline By Therapeutic Class, 2013 13
Biokine Therapeutics Ltd. - Pipeline By Route of Administration, 2013 14
Biokine Therapeutics Ltd. - Pipeline Products By Mechanism of Action, 2013 15
Biokine Therapeutics Ltd. - Dormant Developmental Projects,2013 16

List of Figures


Biokine Therapeutics Ltd. - Pipeline by Indication, 2013 6
Biokine Therapeutics Ltd. - Pipeline by Stage of Development, 2013 7
Biokine Therapeutics Ltd. - Monotherapy Products in Pipeline, 2013 8
Biokine Therapeutics Ltd. - Pipeline By Therapeutic Class, 2013 13
Biokine Therapeutics Ltd. - Pipeline By Route of Administration, 2013 14
Biokine Therapeutics Ltd. - Pipeline Products By Mechanism of Action, 2013 15

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Probable ATP Dependent RNA Helicase DDX58 (DEAD Box Protein 58 or RIG I Like Receptor 1 or Retinoic Acid Inducible Gene 1 Protein or DDX58 or EC 3.6.4.13) - Pipeline Review, H2 2016 Summary Global Markets ...

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC 1.16.3.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Frataxin Mitochondrial (Friedreich Ataxia Protein or FXN or EC ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.